^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Beianting (bevacizumab biosimilar)
i
Other names: MIL 60, MIL60
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Mabworks Biotech, Betta Pharma, Chinese PLA General Hospital
Drug class:
VEGF-A inhibitor
Related drugs:
over1year
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. (PubMed, Lancet Oncol)
In this interim analysis, sintilimab plus IBI305 plus cisplatin and pemetrexed was generally efficacious and well tolerated in patients with EGFR-mutated NSCLC who progressed after receiving EGFR tyrosine-kinase inhibitor therapy.
P3 data • P3 data: top line • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
cisplatin • Tyvyt (sintilimab) • pemetrexed • Byvasda (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar)
3years
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
No abstract available
Clinical • New P2 trial
|
ALB (Albumin)
|
Avastin (bevacizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Onivyde (nanoliposomal irinotecan) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
over3years
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (clinicaltrials.gov)
P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
Clinical • New P2 trial
|
ALB (Albumin)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
almost4years
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
P2; N=96; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2020 --> Jun 2021; Trial primary completion date: Jun 2020 --> Jun 2021
Trial completion date • Trial primary completion date • Clinical
|
MSLN (Mesothelin)
|
MSLN positive
|
Oncomine™ Dx Target Test
|
Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
Share via
